Indacaterol

證據等級: L5

預測適應症: 10 個

Indacaterol: From COPD to Asthma (Bronchial Disease)

One-Sentence Summary

Indacaterol is an ultra-long-acting β₂-adrenoceptor agonist (ultra-LABA) approved globally for once-daily maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD), though it has no current SAHPRA registration in South Africa. The TxGNN model predicts it may be effective for Bronchial Disease (Asthma) — a mechanistically related airway condition — with multiple completed Phase 3 RCTs (including trials enrolling over 6,000 patients) and 20 publications supporting this direction.

Note on TxGNN ranking: The highest-ranked TxGNN prediction was nephrogenic syndrome of inappropriate antidiuresis (score 99.54%, Rank #1 in this pack), but no supporting clinical trials or literature were identified for that indication. Bronchial disease (Asthma) (score 99.18%, TxGNN Rank #7 in this pack) was selected as the primary focus of this report due to its L1 evidence base, direct mechanistic alignment, and actionability for South African healthcare professionals.

Quick Overview

Item	Content
Original Indication	COPD — globally approved; no SAHPRA registration on record
Predicted New Indication	Bronchial Disease (Asthma)
TxGNN Prediction Score	99.18% (TxGNN global rank: #4,184)
Evidence Level	L1
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Although formal mechanism of action data was not retrieved in this evidence pack, Indacaterol is well-established in the pharmacological literature as an ultra-long-acting selective β₂-adrenoceptor agonist (ultra-LABA). Upon inhalation, Indacaterol binds with high affinity and selectivity to β₂-adrenoceptors on bronchial smooth muscle cells, activating adenylyl cyclase and raising intracellular cyclic AMP (cAMP) levels. This cAMP–protein kinase A (PKA) cascade produces sustained smooth muscle relaxation and once-daily bronchodilation lasting 24 hours. Additionally, β₂-receptor activation stabilises airway mast cells — reducing histamine and leukotriene release — and enhances mucociliary clearance.

COPD and asthma both involve chronic airway obstruction with clinically significant bronchospasm, making β₂-agonism pharmacologically relevant to both. Asthma specifically features reversible bronchoconstriction driven by mast cell activation, IgE-mediated airway inflammation, and smooth muscle hyperresponsiveness — precisely the pathophysiological targets of Indacaterol’s mechanism. The transition from COPD to asthma represents one of the shortest mechanistic leaps in drug repurposing: the same receptor, the same airway, and the same pharmacological principle.

In practice, Indacaterol has been extensively studied as part of fixed-dose combination products for asthma. Multiple large Phase 3 trials confirm efficacy in inadequately controlled asthma, and the European Medicines Agency (EMA) has approved Indacaterol-containing products (Enerzair® Breezhaler® and Atectura® Breezhaler®) for asthma maintenance. A critical clinical caveat: international asthma guidelines (GINA) recommend LABA therapy only in combination with an inhaled corticosteroid (ICS); Indacaterol must not be used as monotherapy for asthma due to the established class risk of asthma-related death with LABA alone.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02571777	Phase 3	Completed	3,092	52-week RCT comparing QVM149 (Indacaterol/Glycopyrronium/Mometasone triple combination) vs QMF149 (Indacaterol/Mometasone) in poorly controlled asthma; assessed FEV₁ and asthma control
NCT02554786	Phase 3	Completed	2,216	52-week triple-blind RCT comparing QMF149 (Indacaterol/Mometasone) at two dose levels versus Mometasone monotherapy in inadequately controlled asthma
NCT00941798	Phase 2	Completed	2,283	Large event-driven safety study of QMF149 (Indacaterol/Mometasone) vs Mometasone alone in asthma; primary endpoint: serious asthma exacerbations, hospitalisation, intubation, and death
NCT03158311	Phase 3	Completed	1,426	24-week non-inferiority RCT: fixed-dose QVM149 vs free combination salmeterol/fluticasone + tiotropium in uncontrolled moderate-to-severe asthma
NCT00529529	Phase 3	Completed	805	26-week double-blind RCT assessing safety of Indacaterol 300 μg and 600 μg once daily vs salmeterol 50 μg twice daily in moderate-to-severe persistent asthma
NCT00545272	Phase 2	Completed	392	14-day dose-ranging RCT of four Indacaterol doses via TWISTHALER® vs placebo and formoterol; established effective dose range in adults and adolescents with persistent asthma
NCT01079130	Phase 3	Completed	511	14-day RCT comparing bronchodilator efficacy of multiple Indacaterol doses versus placebo and salmeterol in persistent asthma
NCT04259164	Phase 3	Completed	28	Crossover RCT evaluating anti-inflammatory effects of adding Glycopyrronium to Indacaterol/Mometasone on the allergen-induced late asthmatic response
NCT05217810	PMS	Recruiting	600	24-week real-world post-marketing surveillance for Atectura® (QMF149) mandated by local health authority; evaluates safety and effectiveness under routine clinical practice
NCT00556673	Phase 2	Completed	31	Exploratory crossover study evaluating single-dose bronchodilatory efficacy of Indacaterol/Mometasone via TWISTHALER® in persistent asthma, with Seretide® as active control

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32653074	2020	Phase 3 RCT	The Lancet Respiratory Medicine	IRIDIUM study: once-daily MF–IND–GLY (Mometasone/Indacaterol/Glycopyrronium) was superior to ICS–LABA combinations in patients with inadequately controlled asthma; demonstrated added benefit of the LAMA component
39905183	2025	Systematic Review & Meta-analysis	Scientific Reports	Compared extra-fine BDP/FOR/GLY versus other triple therapies (including Indacaterol-based regimens) in uncontrolled asthma; confirmed superiority of triple fixed-dose inhalers over dual therapy
33871819	2021	Systematic Review	Drugs	Comprehensive review of Indacaterol/Glycopyrronium/Mometasone (Enerzair® Breezhaler®); summarises Phase 3 evidence underpinning EU approval for inadequately controlled asthma in adults
33711782	2021	Pooled Safety Analysis	Respiratory Medicine	Pooled cardiovascular safety analysis of MF/IND and MF/IND/GLY from Phase 3 trial data; demonstrated an acceptable cardiovascular safety profile for Indacaterol-containing combinations in asthma
34783265	2022	Clinical Review	Expert Review of Respiratory Medicine	Positions IND/GLY/MF triple fixed-dose combination as a step-up option for patients with moderate-to-severe asthma failing ICS–LABA therapy; reviews clinical evidence and practical use
32967685	2020	PK/Clinical Study	Respiratory Research	Compared lung function, pharmacokinetics, and tolerability of inhaled Indacaterol maleate (COPD salt) vs acetate (asthma combination salt); provided bridging data supporting the formulation switch
28768531	2017	Randomised Crossover Study	Respiratory Research	Quantified bronchoprotective effects of Glycopyrronium and Indacaterol (monotherapy and combination) on methacholine dose-response curves in mild asthmatics; elucidated synergistic mechanism
34329722	2021	PK Bridging Study	Pulmonary Pharmacology & Therapeutics	Established dose equivalence of Mometasone across QMF149 and QVM149 fixed-dose combinations; provided regulatory basis for approved doses used in asthma treatment
24247039	2014	Review	Current Opinion in Pulmonary Medicine	Reviews ultra-LABA pharmacology (including Indacaterol) and their emerging role in asthma management alongside ICS; discusses novel bronchodilator targets under investigation
31425937	2019	Review	Respiratory Medicine	Summarises the clinical evidence for ultra-LABAs (abediterol, Indacaterol, olodaterol, vilanterol) in asthma; concludes that ICS co-administration is mandatory and that once-daily dosing improves adherence

South Africa Market Information

Indacaterol currently has no SAHPRA registrations in South Africa. The drug is not marketed locally under any brand name or dosage form.

Registration Number	Product Name	Dosage Form	Approved Indication
No SAHPRA registrations on record	—	—	—

Globally, Indacaterol-containing products include:

Onbrez® Breezhaler® (Indacaterol maleate monotherapy, 150 μg and 300 μg) — approved for COPD maintenance in the EU, Japan, and multiple markets
Atectura® Breezhaler® (QMF149: Indacaterol acetate / Mometasone furoate, 150/80 μg, 150/160 μg, 150/320 μg) — approved for asthma maintenance in the EU
Enerzair® Breezhaler® (QVM149: Indacaterol acetate / Glycopyrronium bromide / Mometasone furoate, 150/50/80 μg, 150/50/160 μg) — approved for asthma maintenance in the EU, with digital sensor option

Healthcare professionals requiring access in South Africa would currently need Section 21 (unregistered medicine) authorisation from SAHPRA, or await a formal registration submission by the manufacturer.

Safety Considerations

Formal safety data (package insert warnings, contraindications, and drug interaction data) were not available in this evidence pack, and no SAHPRA-approved Professional Information (PI) exists for this drug in South Africa.

Prescribers should consult the EMA Summary of Product Characteristics (SmPC) for the relevant Indacaterol-containing product. Report any adverse drug reactions to SAHPRA via the MedSafety reporting system.

Key class-effect safety considerations based on LABA pharmacology:

LABA monotherapy in asthma is contraindicated — associated with increased risk of serious asthma-related adverse events including death. Must always be combined with an ICS when used in asthma
Cardiovascular monitoring: Watch for tachycardia, palpitations, and QTc prolongation at supratherapeutic doses; use with caution in patients with known cardiac arrhythmias
Metabolic: Monitor for hypokalaemia (especially when combined with corticosteroids or diuretics) and hyperglycaemia in patients with diabetes mellitus
Post-inhalation cough: A well-documented tolerability issue specific to the Breezhaler® capsule-based dry powder inhaler; generally transient but may affect adherence
Renal and hepatic impairment: No dose adjustment typically required but formal data in severe impairment are limited

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple large Phase 3 RCTs (individual trials enrolling 511 to 3,092 participants) and formal EU regulatory approvals strongly support the use of Indacaterol-containing fixed-dose combinations for the treatment of inadequately controlled asthma. The mechanistic basis is directly aligned with asthma pathophysiology, and the progression from COPD to asthma represents a well-supported and low-risk mechanistic leap. The primary constraint is the complete absence of SAHPRA registration in South Africa, which must be addressed before routine clinical use.

To proceed, the following is needed:

Regulatory pathway: Initiate SAHPRA registration for one or more Indacaterol-containing products (Atectura® Breezhaler® and/or Enerzair® Breezhaler® are the most evidence-supported for asthma). Apply for Section 21 authorisation for individual patient access in the interim
Prescribing restriction: Any use in asthma must be restricted to combination with an ICS — monotherapy in asthma is not supported by evidence and carries a class-level safety risk
Patient selection criteria: Target patients with inadequately controlled asthma on medium-to-high dose ICS or ICS–LABA combinations, in line with GINA Step 4–5 and the IRIDIUM trial population
Pharmacovigilance: Establish a post-marketing surveillance and adverse event reporting plan compliant with SAHPRA requirements
Essential Medicines List (EML) assessment: Evaluate appropriateness for inclusion on the South African EML, given the high burden of asthma in South Africa and the once-daily dosing advantage supporting adherence in resource-constrained settings
Local paediatric data: Consider initiating or participating in South African cohorts for paediatric data (evidence for children 6–12 years is still being generated globally: NCT05562466, NCT02892019)
Formal MOA documentation: Retrieve and file full DrugBank and SAHPRA-compatible MOA documentation to support the registration dossier

This report is generated for research and evaluative purposes only. It does not constitute medical advice or a therapeutic recommendation. All repurposing candidates require prospective clinical validation and regulatory approval before clinical application. Adverse drug reactions should be reported to SAHPRA.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.